Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma 4Hodgkin Disease 4Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Leukemia 3Hematologic Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Kidney Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomatitis 1Stomach Neoplasms 1

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × Diphenhydramine × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡